

## Slavery and Human Trafficking Statement (Fiscal Year 2021)

This statement is made in accordance with Section 54(1) of the United Kingdom Modern Slavery Act 2015. This statement covers the fiscal year from 1 April 2021 to 31 March 2022 disclosing the steps taken by the Daiichi Sankyo Group (hereinafter the "Group") to help prevent modern slavery and human trafficking.

The Group strongly recognizes the need to promote respect for human rights in our business activities and supply chain and is committed to acting with respect for human rights. Our commitment includes the prohibition of modern slavery and human trafficking.

# 1. The Group's Business and Supply Chain

The Group operates in 26 countries with a mission "To contribute to the enrichment of quality of life around the world through the creation of innovative pharmaceuticals, and through the provision of pharmaceuticals addressing diverse medical needs."

Daiichi Sankyo Co., Ltd. is the headquarters of the Group, established in Japan and listed on the Tokyo Stock Exchange. Daiichi Sankyo UK Ltd. is a private limited company of the Group, established in the United Kingdom with "wholesale of pharmaceutical goods" as its principal business activity.

The Group's supply chain consists of suppliers of raw materials (such as active pharmaceutical ingredients, sub-materials and packaging materials), formulations, products and equipment related to our products, as well as suppliers of services related to our business activities (including contract research organizations (CROs) and professional services such as research and management, and sales agents), and we promote "responsible supply chain management", which is important to our business.

#### 2. Policy Regarding Modern Slavery and Human Trafficking

The Group has declared its commitment to respect human rights in the Daiichi Sankyo Group Corporate Conduct Charter that specifies

Daiichi-Sankyo

Passion for Innovation.
Compassion for Patients.™

- Group Employee Code of Conduct that specifies the principles by which all executives and employees including contractors are expected to conduct their work and embed respect for human rights in their work. The Daiichi Sankyo Group Human Rights Policy (hereinafter the "Human Rights Policy") outlines our approach to human rights and further describes our commitment to respect international norms and principles, such as the Universal Declaration of Human Rights and the United Nations Guiding Principles on Business and Human Rights. Daiichi Sankyo Co., Ltd. is also a signatory to the United Nations
- Global Compact and supports the 10 principles covering the 4 areas of human rights, labour, the environment and anti-corruption. In the Human Rights Policy, we have expressed our commitment to enhance respect for human rights in accordance with the Business Partner Code of Conduct, which requires business partners to prohibit modern slavery including forced labour and child labour. Likewise, we have committed to address human rights issues including forced labour and child labour in our workplace.
- 3. Risk Assessment and Human Rights Due Diligence Process

The Group is committed to conducting human rights due diligence based on risk assessment in order to prevent modern slavery and human trafficking in line with the Human Rights Policy.

Specifically, we achieve this by firstly identifying potential human rights risks connected to our business operations, then confirming the status of our efforts on the human rights issues related to these risks, and after that attaining process improvements.

In addition, to promote "responsible supply chain management", we identified categories of suppliers related to our business, and have been conducting human rights risk assessments, and monitoring them through the contract period.

The following were our key initiatives in fiscal year 2021:

· In fiscal year 2021, we conducted feedback on the risk assessment questionnaire survey which was carried out in fiscal year 2020 for all group companies conducting business operations, and it included

Daiichi-Sankyo

Passion for Innovation.
Compassion for Patients.™

- questions about the dissemination of human rights policies, status of addressing human rights issues, stakeholder engagement and the operation of reporting channels. We have shared the group-wide assessment results with Group companies and checked for the items that require confirmation of each company's responses.
- · Since fiscal year 2017, we have been conducting a "Sustainable Procurement Survey" for our major business partners, which takes three years as one cycle, and communication activities to seek their understanding of our approach to sustainable procurement. The "Sustainable Procurement Survey" also includes questions regarding forced labour and child labour. The second survey has been implemented since fiscal year 2020. We updated the questionnaire and conducted the survey targeting 403 major business partners and we have reviewed 386 responses as of the end of fiscal year 2021. No issues related to modern slavery or human trafficking were reported in this survey.
- In Fiscal year 2021, the Group has since introduced a new business partner management program to manage risks related to human rights in Japan. The Group is in the process of introducing this program in Europe to have a unified global due diligence process in place.
- In addition, to promote socially responsible procurement practices by Group companies in Europe, a business partner management system was introduced, and the inherent risk of significant business partners for direct materials, indirect services and other business partners identified as critical were assessed based on the answers they provided. Information collected includes, but is not limited to, Anti-Bribery/Anti-Corruption, Human Rights & Labour, Health & Safety, etc. If we obtain evidence that a business partner has deviated from their CSR commitment, the case is analyzed and escalated to the appropriate instance in order to define the appropriate actions to mitigate the risk. To date (fiscal year 2020 and 2021), a total of 97 business partners have been assessed and monitored with no incidences of modern slavery identified.

Daiichi-Sankyo

Passion for Innovation. Compassion for Patients.™

#### 4. Remedies

The Group has established and operates non-retaliation whistle-blowing systems such as a global hotline, which is available to individuals outside the Group as well as employees of the Group for reporting and consultation in 19 languages, including Japanese and English. Allegations of non-compliance, including but not limited to forced labour regarding procurement, can be raised through these systems. The reporting systems also include counselling on harassment and are designed for reporting and discussing human rights issues in the workplace. In fiscal year 2021, there were no reports of identified issues related to modern slavery and human trafficking.

#### 5. Evaluation of Effectiveness of the Preventive Measures

The Group implements the following activities to monitor the effectiveness of measures taken to prevent modern slavery and human trafficking in our business and supply chain.

- Review of the survey result for Group companies about the status of addressing human rights issues
- Review of the "Sustainable Procurement Survey" result collected from our business partners
- Monitor modern slavery and human trafficking related concerns raised through the whistle-blowing systems

#### 6. Training

The following are our training programmes related to human rights, conducted in fiscal year 2021

- Training on human rights has been completed globally.
- Training on the business partner management system has been completed in Europe.
- Training on procurement compliance has been completed for employees in charge of procurement operations in Japan.

We aim to build a culture of respect for human rights in our work and business at the Group, and embedding this approach is an ongoing process of continuous improvement.

This statement was approved by the Board of Directors of Daiichi Sankyo UK

Daiichi-Sankyo

Passion for Innovation. Compassion for Patients.™

Ltd. on 21 June 2022 and the Board of Directors of Daiichi Sankyo Co., Ltd. on 27 June 2022.

Daiichi Sankyo UK Ltd. has delegated its signature on this statement to Daiichi Sankyo Co., Ltd.

27 June 2022

Sunao Manabe

Daiichi Sankyo Co., Ltd.

8. Enale

Representative Director, Member of the Board, President and CEO